Governments in Europe must to do a lot more to ensure R&D innovation in the biotechnology industry is converted into new companies, new products and extra jobs, according to a new report released earlier today. The report, titled “What Europe has to offer biotechnology companies: unravelling the tax, financial and regulatory framework”, was launched by
The UK’s SkyePharma has succeeded in salvaging some jobs which were threatened by cost-cutting at their Research and Development facility in Muttenz, Switzerland. The jobs were saved as a result of consolidating their relationship with Aenova, the German group whose French subsidiary leased SkyePharma’s manufacturing department at Saint Quentin-Fallavier, Lyon in August 2011.
Earlier today Roche announced the opening of their new R&D office in Basel, Switzerland. The building, which represents an investment of CHF 250 million, will be used to study and develop pharmaceutical formulations for new active ingredients, as well as produce supplies for global clinical trials. Headquartered in Basel, Roche is a leader in research-focused
A new study has found that leading research-based pharmaceutical firms have seen the average quantity of compounds in their late-stage development pipelines drop by 22% this year, while R&D costs have increased by over 25%. According to the 2011 yearly review of pharmaceutical R&D value, Measuring the Return from Innovation, by Deloitte and Thomson Reuters,
